SynthesisPharmacoepidemiology and drug safety2013
Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies.
Synthesis in Pharmacoepidemiology and drug safety, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Efficacy and safety of selective COX-2 inhibitors for pain management after third molar removal: a meta-analysis of randomized clinical trials.Clinical oral investigations · 2020Pooled it
- Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.BMJ (Clinical research ed.) · 2017Pooled it
- Trial
- Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).European heart journal · 2017Trial
- In Patients Experiencing Pain and Inflammation, the Use of Non-Steroidal Anti-Inflammatory Drugs Is More Likely a Marker of the Observed Cardiovascular Risk Rather than Its Cause: A Viewpoint.Pharmacy (Basel, Switzerland) · 2026Review
- Choosing a nonsteroidal anti-inflammatory drug for pain.Australian prescriber · 2025Review
- New Evidence on Diclofenac: Implications for Cardiovascular Safety.Cardiovascular drugs and therapy · 2025Article
- Overall compilation of adverse effects of non-steroidal anti-inflammatory drugs: a hypothesis-free systematic investigation using a nationwide cohort study.Frontiers in pharmacology · 2025Article
- Article
- High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases.Drug safety · 2022Article
- Women With Osteoarthritis Are at Increased Risk of Ischemic Stroke: A Population-Based Cohort Study.Journal of epidemiology · 2021Article
- Management of Osteoarthritis: Expert Opinion on NSAIDs.Pain and therapy · 2021Review
- Safety considerations during prescription of non-steroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews.Anales del sistema sanitario de Navarra · 2021Review
- Database Analysis on the Relationships Between Nonsteroidal Anti-inflammatory Drug Treatment Variables and Incidence of Acute Myocardial Infarction in Japanese Patients with Osteoarthritis and Chronic Low Back Pain.Advances in therapy · 2021Article
- Acute anterior myocardial infarction during myopericarditis treatment in a very young adult.Anatolian journal of cardiology · 2020Article
- Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.Drug safety · 2020Review
- Pharmacologically pertinent period of effect (PPPE).Pharmacoepidemiology and drug safety · 2020Review
- [Pharmacological treatment of osteoarthritis-related pain].Schmerz (Berlin, Germany) · 2019Review
- A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use.Journal of thrombosis and thrombolysis · 2019Review
- Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo conduct a systematic review of observational studies on the risk of acute myocardial infarction (AMI) with use of individual nonsteroidal anti-inflammatory drugs (NSAIDs).
methodsA search of Medline (PubMed) for observational studies published from 1990 to 2011 identified 3829 articles; 31 reported relative risk (RR) of AMI with use of individual NSAIDs versus nonuse of NSAIDs. Information abstracted in a standardized form from 25 publications was used for the meta-analysis on 18 independent study populations.
resultsRandom-effects RR (95% confidence interval (CI)) was lowest for naproxen 1.06 (0.94–1.20), followed by celecoxib 1.12 (1.00–1.24), ibuprofen 1.14 (0.98–1.31), meloxicam 1.25 (1.04–1.49), rofecoxib 1.34 (1.22–1.48), diclofenac 1.38 (1.26–1.52), indometacin 1.40 (1.21–1.62), etodolac 1.55 (1.16–2.06), and etoricoxib 1.97 (1.35–2.89). Heterogeneity between studies was present. For new users, RRs (95% CIs) were for naproxen, 0.85 (0.73–1.00); ibuprofen, 1.20 (0.97–1.48); celecoxib, 1.23 (1.00–1.52); diclofenac, 1.41 (1.08–1.86); and rofecoxib, 1.43 (1.21–1.66).Except for naproxen, higher risk was generally associated with higher doses, as defined in each study, overall and in patients with prior coronary heart disease. Low and high doses of diclofenac and rofecoxib were associated with high risk of AMI, with dose–response relationship for rofecoxib. In patients with prior coronary heart disease, except for naproxen, duration of use ≤3 months was associated with an increased risk of AMI.
conclusionsMost frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or in persons with diagnosed coronary heart disease. For diclofenac and rofecoxib, the risk was increased at low and high doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.